These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 36298823)

  • 1. HIV-1 pathogenesis and therapeutic intervention in the SCID-hu Thy/Liv mouse: a model for primary HIV-1 infection in the human thymus.
    Su L
    Rev Med Virol; 1997 Sep; 7(3):157-166. PubMed ID: 10398480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Activity and Crystal Structures of HIV-1 gp120 Antagonists.
    Curreli F; Kwon YD; Nicolau I; Burgos G; Altieri A; Kurkin AV; Verardi R; Kwong PD; Debnath AK
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SCID-hu mice: a model for studying disseminated HIV infection.
    Goldstein H; Pettoello-Mantovani M; Katopodis NF; Kim A; Yurasov S; Kollmann TR
    Semin Immunol; 1996 Aug; 8(4):223-31. PubMed ID: 8883145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Pharmacokinetics of a Dual Inhibitor of HIV-1, NBD-14189, in Rats and Dogs with a Proof-of-Concept Evaluation of Antiviral Potency in SCID-hu Mouse Model.
    Stoddart CA; Curreli F; Horrigan S; Altieri A; Kurkin AV; Debnath AK
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues.
    Pettoello-Mantovani M; Kollmann TR; Raker C; Kim A; Yurasov S; Tudor R; Wiltshire H; Goldstein H
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1880-7. PubMed ID: 9303378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.
    Stoddart CA; Bales CA; Bare JC; Chkhenkeli G; Galkina SA; Kinkade AN; Moreno ME; Rivera JM; Ronquillo RE; Sloan B; Black PL
    PLoS One; 2007 Aug; 2(7):e655. PubMed ID: 17668043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV hollow fiber SCID model for antiviral therapy comparison with SCID/hu model.
    Taggart BR; Harrington P; Hollingshead M
    Antiviral Res; 2004 Jul; 63(1):1-6. PubMed ID: 15196814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a novel transgenic mouse/SCID-hu mouse system to characterize the in vivo behavior of reservoirs of human immunodeficiency virus type 1-infected cells.
    Wang EJ; Pettoello-Mantovani M; Anderson CM; Osiecki K; Moskowitz D; Goldstein H
    J Infect Dis; 2002 Nov; 186(10):1412-21. PubMed ID: 12404156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model.
    Honeycutt JB; Wahl A; Archin N; Choudhary S; Margolis D; Garcia JV
    Retrovirology; 2013 Oct; 10():121. PubMed ID: 24156277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why 90% of clinical drug development fails and how to improve it?
    Sun D; Gao W; Hu H; Zhou S
    Acta Pharm Sin B; 2022 Jul; 12(7):3049-3062. PubMed ID: 35865092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
    Williams J; Siramshetty V; Nguyễn ÐT; Padilha EC; Kabir M; Yu KR; Wang AQ; Zhao T; Itkin M; Shinn P; Mathé EA; Xu X; Shah P
    Bioorg Med Chem; 2022 Feb; 56():116588. PubMed ID: 35030421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fostemsavir: a first-in-class HIV-1 attachment inhibitor.
    Grant PM; Kozal MJ
    Curr Opin HIV AIDS; 2022 Jan; 17(1):32-35. PubMed ID: 34871189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites.
    Losada N; Ruiz FX; Curreli F; Gruber K; Pilch A; Das K; Debnath AK; Arnold E
    J Med Chem; 2021 Nov; 64(22):16530-16540. PubMed ID: 34735153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
    Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
    Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.